北京若生智能科技有限公司
Drug Database
CA

cannabidiol (Xalex 10)

✓ Approved

RAMM Pharma · CNR1

什么是 cannabidiol？

cannabidiol 是一种治疗药物，由RAMM Pharma研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Xalex 10
公司RAMM Pharma
分子靶点CNR1, TRPV1, GPR55
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, RAMM Pharma

作用机制

分子靶点

cannabidiol 作用于 3 个分子靶点：

CNR1cannabinoid receptor 1 (CNR, CB1A)
TRPV1transient receptor potential cation channel subfamily V member 1 (VR1)
GPR55G protein-coupled receptor 55 (LPIR1)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

cannabidiol 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersEpilepsy✓ Approved

相关研究文献

PubMedNarra J2026-09-11

Herbal products for the prevention and management of 5-fluorouracil-induced oral mucositis: A systematic review of preclinical evidence.

Astari Pocut P, Suniarti Dewi F DF, Idrus Erik E

Oral mucositis is a painful and dose-limiting complication of chemotherapy, particularly in patients receiving 5-fluorouracil (5-FU). Herbal products have attracted increasing interest as supportive care candidates because of their antioxidant, anti-inflammatory, anti-apoptotic, and cytoprotective properties. This systematic review aimed to synthesize preclinical evidence on the effects and mechanisms of herbal products in 5-FU-induced oral mucositis models. A literature search was conducted in PubMed, Scopus, EBSCO, ScienceDirect, and ProQuest for studies published up to March 2026, following PRISMA guidelines. Eligible studies were in vitro studies, or studies with a clearly described in vitro component, that evaluated herbal extracts, multi-herbal formulations, or naturally derived plant-based compounds in 5-FU-induced oral mucositis models. Study reliability was assessed using the ToxRTool. Seven studies were included, comprising three in vitro-only studies and four combined in vitro-in vivo experimental studies published between 2014 and 2025. The evaluated products included Daiokanzoto, Salvia miltiorrhiza, Onchung-eum, anthocyanins from Oryza sativa, FITOPROT, cannabidiol, and Camellia tea saponin. Across the included studies, herbal products were reported to improve cell viability, reduce reactive oxygen species production, suppress inflammatory mediators, inhibit apoptosis, and promote epithelial repair. The main mechanisms involved the modulation of nuclear factor kappa-light-chain-enhancer of activated B cells signaling, caspase-3 activation, the Nrf2/Keap1/ARE pathway, mitochondrial dysfunction, and ferroptosis-related markers. All included studies were classified as reliable without restrictions, with ToxRTool scores ranging from 16 to 18. In conclusion, preclinical evidence suggests that herbal products may have protective effects against 5-FU-induced oral mucositis through antioxidant, anti-inflammatory, and cytoprotective mechanisms. However, standardized in vivo studies and clinical trials are needed before their therapeutic use can be recommended.

PMID 42724054
阅读全文 →
PubMedJournal of endodontics2026-09-10

Combined Cannabidiol and Δ9-Tetrahydrocannabinol Modulate Inflammation and Nociceptive Signaling in Human Dental Pulp Cells.

Soe Zar Chi ZC, Nan Daneeya Na DN, Wahyudi Rahman R, Sriwattanapong Kanokwan K et al.

Dental pulp inflammation, caused by caries, trauma, or restorative operations, produces pain and slows regeneration. Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), cannabinoids of Cannabis sativa, have effects on inflammation and pain relief. However, the impact of these factors on dental pulp healing is not understood. This study investigated the combined effects of CBD and THC in controlling inflammation and nociception during dental pulp repair. Human dental pulp cells were stimulated with lipopolysaccharide (LPS) and treated with CBD (2.5 μg/mL), THC (0.6 μg/mL), and their combination. Pro-inflammatory cytokines (IL-6, IL-12 and IL-1β) and anti-inflammatory cytokine IL-10 were analysed using qPCR and ELISA, while anti-nociceptive markers (CNR1, CNR2, and TRPV1) were evaluated by qPCR and Western blot. Cell viability, proliferation, and migration assays were performed to evaluate treatment effects on cellular behaviours associated with pulpal repair and regenerative potential. Compared with either treatment alone, the CBD/THC combination more effectively attenuated pro-inflammatory cytokines IL-6, IL-12, and IL-1β, enhanced CNR1 and CNR2 expression, modulated TRPV1, and increased IL-10 expression. Viability assays determined optimal non-cytotoxic concentrations for treatment. The combination enhanced cell proliferation and migration, promoted mineralized nodule formation, and significantly upregulated markers associated with tissue repair, odontogenic differentiation (DMP1), and angiogenesis (VEGF and bFGF). Combined CBD and THC show promise for promoting dental pulp healing by modulating inflammation and nociceptive signaling, while supporting odontogenic differentiation, angiogenesis, and cell migration in human dental pulp cells. These findings provide in vitro evidence supporting combined cannabinoid treatment as a therapeutic strategy for vital pulp therapies.

PMID 42722230
阅读全文 →
PubMedExplore (New York, N.Y.)2026-09-10

A modern take on the health effects of cannabis use: The future of cannabis research.

Jelinsky Andy A, Zelikoff Judith T JT

Cannabis use has increased greatly in the US since legalization occurred in many states, particularly by young adults ages 18-26. Recent survey data suggest that many young adults see smoking cannabis as carrying a low health risk, especially when compared to drinking alcohol or smoking tobacco. However, there is laboratory research and human health data suggesting that cannabis smoke has the potential to cause harm to users. A positive correlation between cannabis smoking and psychotic episodes has been established, as well as with respiratory symptoms such as chronic bronchitis. Research suggests that young adults are at particular risk for cognitive effects, and that cessation can improve health outcomes. Although, it is not possible to establish a definitive correlation between cannabis smoking and severe health outcomes such as cancer or other chronic diseases due to insufficient existing data and the technical limitations of the study designs. The gap in knowledge on cannabis health effects can be explained by various factors, including but not limited to insufficient quantities of clinical data, flawed study design, failure to account for the various methods of cannabis smoking, methods of cannabis use that do not involve smoking, dual use of tobacco or other substances by study participants, and an incomplete understanding of the pharmacology of cannabis and its non-psychoactive compounds. A complete knowledge of potential benefits of cannabis use is equally lacking; preliminary evidence suggests cannabis may possess anti-inflammatory properties, though these benefits have not yet been fully characterized or supported by sufficient clinical or basic research. While the Food and Drug Association (FDA) has approved the use of several cannabis-derived compounds such as cannabidiol (CBD) to treat select medical conditions, the use of cannabis itself has not received regulatory approval for treating any medical conditions. Due to the incomplete knowledge of any potential health effects of cannabis use, caution is advised to those considering the use of cannabis, particularly young adults.

PMID 42721601
阅读全文 →
PubMedThe AAPS journal2026-09-09

Predicting Cannabidiol Pharmacokinetics in Older Adults Via Physiologically Based Pharmacokinetic Modeling.

Qian Lixuan L, Nguyen Aiden-Hung P AP, Paine Mary F MF, Zhou Zhu Z

Cannabidiol (CBD) use continues to increase, particularly among older adults. However, knowledge of CBD disposition in this ever-growing and understudied population, along with the relative contributions of cytochrome P450 (CYP) and uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes to CBD metabolism, remain limited. Inclusion of UGT activators (e.g., alamethicin, MgCl2) may alter in vitro estimates of enzyme contributions. CBD has also been reported to produce time-dependent inhibition (TDI) of certain CYPs, potentially affecting its own disposition. We combined in vitro data with physiologically based pharmacokinetic (PBPK) modeling to further characterize TDI and reversible CYP inhibition by CBD, quantify the contributions of CYPs and UGTs to CBD metabolism, and determine in vitro assay conditions that best reflect in vivo CBD metabolism. PBPK modeling was next used to extrapolate CBD exposure from young (18-64 years) to older (65-98 years) adults. CBD exhibited TDI only toward CYP1A2, which had a negligible effect on CBD metabolism. Inclusion of alamethicin + MgCl2 increased the apparent contribution by UGTs to CBD metabolism, leading to an overestimate of UGT-mediated metabolism. PBPK model validation using drug-drug interaction studies supported contributions of 86% and 14% for CYPs and UGTs, respectively, as best capturing observed CBD exposure. Simulations in older adults generally showed increased CBD exposure relative to young adults, with the magnitude depending on age and administration route. Overall, these results improve our understanding of CBD pharmacokinetics, support more informed risk assessment in older adults, and provide a more robust foundation for future studies.

PMID 42711610
阅读全文 →
PubMedCNS drugs2026-09-09

Cognitive Side Effects of Antiseizure Medications in Adults with Epilepsy: An Update with a Focus on New Therapeutic Agents.

Mula Marco M

Antiseizure medications (ASMs) are the mainstay of epilepsy treatment but may adversely affect cognitive functions, deepening the cognitive and psychosocial burden intrinsic to epilepsy. Cognitive side effects vary widely across drug classes, doses, treatment regimens, and individual susceptibility, typically affecting attention, processing speed, memory, language, and executive function. This narrative review provides an updated synthesis of the clinical evidence on the cognitive effects of ASMs, mostly in adults, building on a prior 2009 review and focusing on agents introduced into clinical practice since then. A literature search of PubMed identified studies published between January 2009 and December 2025, yielding data from randomised controlled trials, observational studies, meta-analyses, and systematic reviews. Overall, newer-generation ASMs, including rufinamide, lacosamide, brivaracetam, cannabidiol, fenfluramine, and ganaxolone, demonstrate generally favourable cognitive profiles when used at recommended doses, particularly in monotherapy or rational polytherapy. Eslicarbazepine and cenobamate may be associated with mild, dose-dependent cognitive effects, occurring only at the upper end of the recommended dose range. In contrast, old ASMs and certain second-generation agents, notably topiramate and zonisamide, remain consistently associated with higher cognitive risks. Special populations, including older adults and individuals with intellectual disabilities, are particularly vulnerable to cognitive adverse effects and benefit from agents with low interaction potential and benign neuropsychological profiles. Cognitive dysfunction in epilepsy is multifactorial, reflecting the interaction between disease-related neurobiological mechanisms and treatment effects. Optimal management requires balancing seizure control with cognitive preservation through individualised drug selection, cautious titration, and minimisation of polytherapy to achieve the best functional and quality-of-life outcomes.

PMID 42714779
阅读全文 →
PubMedPain2026-09-08

Cannabidiol reverses mechanical hypersensitivity in a mouse model of apical periodontitis.

Chrepa Vanessa V, Murillo Josue J, Villasenor Stephany S, Tram Meilinn M et al.

Cannabidiol (CBD) has both analgesic and anti-inflammatory properties. Because CBD is not psychotomimetic, it could be an excellent nonopioid alternative for various pain disorders. The aim was to assess the effectiveness of CBD as an analgesic for apical periodontitis-induced mechanical hypersensitivity (MH), its site of action (peripheral or central), and the potential involvement of transient receptor potential vanilloid 1 (TRPV1), using a mouse behavioral model of apical periodontitis (AP). Male and female mice underwent pulp exposure of the left maxillary first molar (AP group) or sham surgery (Sham group). Mechanical hypersensitivity was assessed 21 days after surgery using von Frey filaments on the left vibrissal pad. Apical periodontitis mice that received a single dose of oral CBD (AP [CBD]) experienced a significant reduction in MH at 45 minutes and 120 minutes compared with AP mice that received vehicle (AP [Veh]). The analgesic effect in males was significantly greater than in females at this CBD dose. Intrathecal and intracisternal (IC), but not ipsilateral intraoral, CBD injections reduced MH in the male AP (CBD) group, indicating a central site of action of CBD in this model of odontogenic pain. Furthermore, intraperitoneal and IC injection of AMG 517 (TRPV1 antagonist) before an oral CBD dose blocked the CBD analgesic effect in male mice, suggesting TRPV1's involvement. Overall, this study shows, for the first time, that oral CBD can be an effective analgesic for apical periodontitis-induced MH. This analgesic effect was mediated through a central site of action and involved the TRPV1 channel.

PMID 42708340
阅读全文 →

注册免费账户还可查看另外 7947 篇文献

免费注册查看全部文献 →

了解更多cannabidiol